About this medicine
- Approved name
- Valbazen 100 mg/ml Total Spectrum Wormer oral suspension and associated names, including its generic/hybrid products
- International non-proprietary name (INN) or common name
- albendazole
About this procedure
- Current status
- European Commission final decision
- Reference number
- EMEA-V-A-140
- Type
- Article 35
Community interest referral: initiated in cases involving the interests of the Community or concerns relating to the protection of human or animal health or the environment.
- Authorisation model
- Centrally and nationally authorised products (mixed)
Key dates and outcomes
- Opinion date
- 05/11/2020
- EC decision date
- 18/01/2021